Drug Profile
NMK 150
Alternative Names: NMK-150Latest Information Update: 11 Aug 2011
Price :
$50
*
At a glance
- Originator Axcan Pharma; Norax
- Developer Aptalis
- Class Peptide hydrolases
- Mechanism of Action Pancrelipase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Visceral pain
Most Recent Events
- 29 Nov 2007 Phase-I development is ongoing
- 08 May 2006 Phase-I clinical trials in Visceral pain in Canada (PO)
- 27 Mar 2003 Preclinical trials in Visceral pain in Canada (unspecified route)